NCT07025018View on ClinicalTrials.gov

Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

PHASE1RecruitingINTERVENTIONAL

Enrollment

52

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Gliomas Harboring IDH1 and/or IDH2 Mutations

Interventions

DRUG

HMPL-306

IDH small molecule inhibitor

Trial Locations (1)

200040

RECRUITING

Huashan Hospital affiliated to Fudan University, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Hutchmed

INDUSTRY

NCT07025018 - Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations | Biotech Hunter | Biotech Hunter